Linagliptin fda approval date?

See the DrugPatentWatch profile for Linagliptin

When did linagliptin get FDA approval?

Linagliptin (brand name Tradjenta) received FDA approval on May 2, 2011. [1]

What was the FDA approval for (and what does it treat)?

Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor used as part of the treatment of type 2 diabetes mellitus. [1]

Patent/exclusivity checks if you’re tracking dates

If you’re looking for related patent or exclusivity timelines for linagliptin, DrugPatentWatch.com tracks those details and can help connect approval timing to later exclusivity and patent events. [2]

Sources
[1] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202049
[2] https://www.drugpatentwatch.com/p/linagliptin